Beaver Run Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2008
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Diabetes Mellitus, Insulin Action and Resistance (A6)
Organizer(s) Mary-Elizabeth Patti and David E. Moller
January 22—27, 2008
Beaver Run Resort • Breckenridge, CO USA
Abstract Deadline: Sep 24, 2007
Late Abstract Deadline: Oct 25, 2007
Scholarship Deadline: Sep 24, 2007
Early Registration Deadline: Nov 26, 2007
Part of the Translational Medicine Series, Sponsored by Pfizer Global Research & Development
Summary of Meeting:
The incidence of type 2 diabetes is increasing worldwide at an alarming rate – mandating intensive efforts to improve our understanding of diabetes pathophysiology, improve options for therapy, and most importantly, to initiate strategies for disease prevention in high-risk groups. This meeting will focus on recent advances in our understanding of the molecular pathogenesis of insulin resistance, diabetes, and related syndromes, with particular emphasis on (1) multi-system nature of diabetes pathophysiology, (2) genetic basis of insulin resistance and diabetes risk, (3) potential links between epigenetic modulation of gene expression and diabetes risk related to “environmental” mechanisms, (4) pathways linking obesity, inflammation, and diabetes risk, and (5) new molecular mechanisms of insulin resistance. Moreover, the meeting will highlight novel pharmacologic targets for diabetes therapy. A key goal of the meeting will also be to facilitate collaborative interactions between basic scientists and translational clinical scientists focused on prevention and treatment of insulin resistance and diabetes.
View Scholarships/Awards
The incidence of type 2 diabetes is increasing worldwide at an alarming rate – mandating intensive efforts to improve our understanding of diabetes pathophysiology, improve options for therapy, and most importantly, to initiate strategies for disease prevention in high-risk groups. This meeting will focus on recent advances in our understanding of the molecular pathogenesis of insulin resistance, diabetes, and related syndromes, with particular emphasis on (1) multi-system nature of diabetes pathophysiology, (2) genetic basis of insulin resistance and diabetes risk, (3) potential links between epigenetic modulation of gene expression and diabetes risk related to “environmental” mechanisms, (4) pathways linking obesity, inflammation, and diabetes risk, and (5) new molecular mechanisms of insulin resistance. Moreover, the meeting will highlight novel pharmacologic targets for diabetes therapy. A key goal of the meeting will also be to facilitate collaborative interactions between basic scientists and translational clinical scientists focused on prevention and treatment of insulin resistance and diabetes.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
TUESDAY, JANUARY 22
WEDNESDAY, JANUARY 23
THURSDAY, JANUARY 24
FRIDAY, JANUARY 25
SATURDAY, JANUARY 26
SUNDAY, JANUARY 27
Conference Program Print | View meeting in 24 hr (international) time
TUESDAY, JANUARY 22
7:30—9:30 PM
Keynote Session
*
David E. Moller,
Eli Lilly and Company, USA
Introductory Remarks
Introductory Remarks
C. Ronald Kahn,
Joslin Diabetes Center and Harvard Medical School, USA
Insulin Resistance, Obesity and Type 2 Diabetes: Which is the Chicken and Which is the Egg?
Insulin Resistance, Obesity and Type 2 Diabetes: Which is the Chicken and Which is the Egg?
Leif C. Groop,
Lund University, Sweden
Searching for the Genetic Causes of Type 2 Diabetes
Searching for the Genetic Causes of Type 2 Diabetes
8:00—11:15 AM
Insulin Resistance and Diabetes Pathogenesis
Ele Ferrannini,
University of Pisa, Italy
Overview: Relative Role of Insulin Resistance vs. Beta Cell Dysfunction in Diabetes Pathogenesis
Overview: Relative Role of Insulin Resistance vs. Beta Cell Dysfunction in Diabetes Pathogenesis
Hannele Yki-Järvinen,
University of Helsinki, Finland
Role of Fatty Liver in the Pathogenesis of Metabolic Syndrome and Type 2 Diabetes
Role of Fatty Liver in the Pathogenesis of Metabolic Syndrome and Type 2 Diabetes
Gerald I. Shulman,
Yale University School of Medicine, USA
Cellular Mechanisms of Insulin Resistance and the Role of Skeletal Muscle Insulin Resistance in the Pathogenesis of the Metabolic Syndrome
Cellular Mechanisms of Insulin Resistance and the Role of Skeletal Muscle Insulin Resistance in the Pathogenesis of the Metabolic Syndrome
Gökhan S. Hotamisligil,
Harvard School of Public Health, USA
Inflammation and ER Stress in Metabolic Disease
Inflammation and ER Stress in Metabolic Disease
Michael Ristow,
Swiss Federal Institute of Technology Zurich - ETH, Switzerland
Short Talk: Impaired Oxidative Phosphorylation Induces Oxidative Stress, Decreases Life Span and Promotes Type 2 Diabetes and Obesity
Short Talk: Impaired Oxidative Phosphorylation Induces Oxidative Stress, Decreases Life Span and Promotes Type 2 Diabetes and Obesity
J. Andrew Pospisilik,
Van Andel Institute, USA
Short Talk: Targeted Deletion of AIF Reduces OxPhos and Prevents Diabetes and Obesity
Short Talk: Targeted Deletion of AIF Reduces OxPhos and Prevents Diabetes and Obesity
12:00—1:30 PM
Meet the Professor Lunch: NIH Grant Application Process and Endo-Related Study Sessions
Box Lunches available for purchase. Advance sign-up will be required.
*
Philip F. Smith,
NIDDK, National Institutes of Health, USA
5:00—7:00 PM
Genetics and Syndromes Related to Type 2 Diabetes
*
Leif C. Groop,
Lund University, Sweden
Philippe Froguel,
Imperial College of London, UK
Human Polygenic Severe Obesity Genes, What's New? What's Interesting?
Human Polygenic Severe Obesity Genes, What's New? What's Interesting?
Leslie J. Baier,
National Institutes of Health, USA
The Search for Type 2 Diabetes and Obesity Susceptibility Genes in Pima Indians
The Search for Type 2 Diabetes and Obesity Susceptibility Genes in Pima Indians
Andrea Dunaif,
Icahn School of Medicine at Mount Sinai, USA
PCOS and Type 2 Diabetes – Insights from Genetic Studies
PCOS and Type 2 Diabetes – Insights from Genetic Studies
Jeremy B.M. Jowett,
Baker IDI Heart and Diabetes Institute, Australia
Short Talk: A Systems Biology Approach to Determining the Biological Consequences of Genetic Variation in Humans: The PPAR gamma Pro12Ala Variant
Short Talk: A Systems Biology Approach to Determining the Biological Consequences of Genetic Variation in Humans: The PPAR gamma Pro12Ala Variant
8:00—11:15 AM
Adipose and Inflammatory Links to Insulin Resistance
*
Michael P. Czech,
University of Massachusetts Medical School, USA
Isaac S. Kohane,
Harvard Medical School, USA
Getting Better and More Numbers for Discovery Research in the Genomic Era
Getting Better and More Numbers for Discovery Research in the Genomic Era
Lily Q. Dong,
University of Texas Health Science Center, USA
Short Talk: “Ying-Yang” Regulation of Adiponectin Signaling by APPL Isoforms
Short Talk: “Ying-Yang” Regulation of Adiponectin Signaling by APPL Isoforms
Rosalind A. Coleman,
University of North Carolina at Chapel Hill, USA
Lipogenic Pathways: Links to Diabetes Risk
Lipogenic Pathways: Links to Diabetes Risk
Steven E. Shoelson,
Harvard Medical School, Joslin Diabetes Center, USA
Potent Roles of the Immune System in Obesity Induced T2DM and CVB
Potent Roles of the Immune System in Obesity Induced T2DM and CVB
Mitchell A. Lazar,
Perelman School of Medicine, University of Pennsylvania, USA
Transcriptional Networks Leading From Obesity to Insulin Resistance
Transcriptional Networks Leading From Obesity to Insulin Resistance
David A. Bernlohr,
University of Minnesota, USA
Short Talk: Role of Adipose Protein Carbonylation in Insulin Resistance; The HNE Pathway
Short Talk: Role of Adipose Protein Carbonylation in Insulin Resistance; The HNE Pathway
12:00—1:30 PM
Meet the Professor Lunch: Clinical DM for PhDs
*
Martin J. Abrahamson,
Harvard Medical School, USA
5:00—7:15 PM
Epigenetic and Metabolic Determinants of Insulin Resistance and Diabetes Risk
Miguel Constância,
University of Cambridge, UK
Epigenetics: Basic Mechanisms and Potential Links to Developmental Origins of Adult Disease
Epigenetics: Basic Mechanisms and Potential Links to Developmental Origins of Adult Disease
Mary-Elizabeth Patti,
Joslin Diabetes Center, USA
Genetic and Environmental Pathways to Human Diabetes Risk
Genetic and Environmental Pathways to Human Diabetes Risk
Don Ayer,
University of Utah, USA
Short Talk: Glucose Sensing and Regulation of Glucose-Dependent Transcription
Short Talk: Glucose Sensing and Regulation of Glucose-Dependent Transcription
Assam El-Osta,
Monash University, Australia
Short Talk: Transient Hyperglycemia Induces Persistent Transcriptional Activity; Insights into Epigenetic Change and Glycemic Memory
Short Talk: Transient Hyperglycemia Induces Persistent Transcriptional Activity; Insights into Epigenetic Change and Glycemic Memory
8:00—11:15 AM
Searching for New Therapeutic Targets
*
David E. Moller,
Eli Lilly and Company, USA
Alan D. Attie,
University of Wisconsin-Madison, USA
Multidimensional Approaches to DM Gene Discovery
Multidimensional Approaches to DM Gene Discovery
Michael P. Czech,
University of Massachusetts Medical School, USA
Systems Biology Approaches to Metabolic Disease
Systems Biology Approaches to Metabolic Disease
Alexei Kharitonenkov,
Novo Nordisk, USA
Metabolic Actions of FGF-21
Metabolic Actions of FGF-21
D. Grahame Hardie,
University of Dundee, UK
AMP-Activated Protein Kinase as a Drug Target in Type 2 Diabetes and Metabolic Syndrome
AMP-Activated Protein Kinase as a Drug Target in Type 2 Diabetes and Metabolic Syndrome
Carsten Schmitz-Peiffer,
Garvan Institute of Medical Research, Australia
Short Talk: Inhibition of PKCepsilon is a Potential Therapy for Type 2 Diabetes by Reconstituting Glucose-Stimulated Insulin Secretion and Reducing Insulin Clearance
Short Talk: Inhibition of PKCepsilon is a Potential Therapy for Type 2 Diabetes by Reconstituting Glucose-Stimulated Insulin Secretion and Reducing Insulin Clearance
Joe S. Grimsby,
AstraZeneca, USA
Short Talk: Antidiabetic Effects of Glucokinase Activators: From Benchside to Bedside
Short Talk: Antidiabetic Effects of Glucokinase Activators: From Benchside to Bedside
2:30—4:30 PM
Drug Discovery Workshop
*
David E. Moller,
Eli Lilly and Company, USA
*
Jin-Long Chen,
NGM Biopharmaceuticals, Inc., USA
Ranabir Sinha Roy,
Merck & Co. Inc., USA
DPP-4 Inhibitors and Next-Generation Insulin Secretagogues
DPP-4 Inhibitors and Next-Generation Insulin Secretagogues
Bryan Goodwin,
Enanta Pharmaceuticals, USA
Orphan Nuclear Receptors and Beyond in the Treatment of Metabolic Disease
Orphan Nuclear Receptors and Beyond in the Treatment of Metabolic Disease
Cord Dohrmann,
Evotec AG, Germany
Identifying Drug Targets Regulating Metabolism in Drosophila
Identifying Drug Targets Regulating Metabolism in Drosophila
Brian Zambrowicz,
Regeneron, USA
Using Mouse Genetics to Understand Gene Function and Identify Targets for Drug Discovery
Using Mouse Genetics to Understand Gene Function and Identify Targets for Drug Discovery
5:00—7:00 PM
Novel Pathways in Diabetes and Metabolic Syndrome
*
Barbara B. Kahn,
Beth Israel Deaconess Medical Center, Harvard Medical School, USA
Philipp E. Scherer,
University of Texas Southwestern Medical Center, USA
Separating “Good” from “Bad” Adipose
Separating “Good” from “Bad” Adipose
Juleen R. Zierath,
Karolinska Institutet, Sweden
Down-Regulation of Diacylglycerol Kinase Delta Contributes to Hyperglycemia-Induced Insulin Resistance
Down-Regulation of Diacylglycerol Kinase Delta Contributes to Hyperglycemia-Induced Insulin Resistance
Pere Puigserver,
Dana-Farber Cancer Institute, Harvard Medical School, USA
Sirtuins and Transcriptional Control in Hepatic Metabolism
Sirtuins and Transcriptional Control in Hepatic Metabolism
Maziyar Saberi,
NGM Biopharmaceuticals, USA
Short Talk: Novel Liver-Specific TORC2 siRNA Corrects Hyperglycemia in Rodent Models of Type 2 Diabetes
Short Talk: Novel Liver-Specific TORC2 siRNA Corrects Hyperglycemia in Rodent Models of Type 2 Diabetes
8:00—11:30 AM
New Molecular Mechanisms of Insulin Resistance
Barbara B. Kahn,
Beth Israel Deaconess Medical Center, Harvard Medical School, USA
RBP4 and Insulin Resistance
RBP4 and Insulin Resistance
Deborah M. Muoio,
Duke University Medical Center, USA
Lipid-Induced Mitochondrial Stress and Insulin Resistance in Skeletal Muscle
Lipid-Induced Mitochondrial Stress and Insulin Resistance in Skeletal Muscle
Joyce J. Repa,
University of Texas Southwestern Medical Center, USA
The Oxysterol Nuclear Receptors and Glucose Homeostasis
The Oxysterol Nuclear Receptors and Glucose Homeostasis
Johan Auwerx,
École Polytechnique Fédérale de Lausanne, Switzerland
A Cofactor Network that Controls PGC-1alpha Activity and Energy Homeostasis
A Cofactor Network that Controls PGC-1alpha Activity and Energy Homeostasis
Alexander S. Banks,
Harvard Medical School, USA
Short Talk: Metabolic Mimicry of Calorie Restriction by SirT1 Gain-of-Function in Mice
Short Talk: Metabolic Mimicry of Calorie Restriction by SirT1 Gain-of-Function in Mice
Matthias Mann,
Max Planck Institute of Biochemistry, Germany
Short Talk: Mapping the Mitochondrial Proteome – Implications for Insulin Action and Diabetes
Short Talk: Mapping the Mitochondrial Proteome – Implications for Insulin Action and Diabetes
Mark A. Febbraio,
Monash Institute of Pharmaceutical Sciences, Australia
Short Talk: Activating HSP72 Protects against Obesity-Induced Insulin Resistance
Short Talk: Activating HSP72 Protects against Obesity-Induced Insulin Resistance
12:00—1:30 PM
Meet the Professor Lunch: Perspectives of Science in Drug Discovery and Careers in Industry
Box Lunches available for purchase. Advance sign-up will be required.
*
David E. Moller,
Eli Lilly and Company, USA
Introduction
Introduction
*
Rebecca A. Taub,
VIA Pharmaceuticals, Inc, USA
*
Thomas A. Gustafson,
Johnson and Johnson, USA
5:00—7:00 PM
Transcriptional Interface between Lipid and Glucose Metabolism
*
Anna Krook,
Karolinska Institutet, Sweden
Marc R. Montminy,
The Salk Institute for Biological Studies, USA
The TORC Family of CREB Coactivators: Regulators of Energy Balance
The TORC Family of CREB Coactivators: Regulators of Energy Balance
Markus Stoffel,
ETH Zürich, Switzerland
Cross-Talk between Insulin Signaling and FOXA2 in the Liver and Lateral Hypothalamus
Cross-Talk between Insulin Signaling and FOXA2 in the Liver and Lateral Hypothalamus
Bruce M. Spiegelman,
Harvard Medical School, USA
Transcriptional Control of Brown Fat Determination by PRDM16: A Co-Regulator of the PGC-1s and Nuclear Receptors
Transcriptional Control of Brown Fat Determination by PRDM16: A Co-Regulator of the PGC-1s and Nuclear Receptors
Jiandie Lin,
University of Michigan Medical School, USA
Short Talk: Decoding the PGC-1 Transcriptional Network through Genome-Wide Coactivation Analyses
Short Talk: Decoding the PGC-1 Transcriptional Network through Genome-Wide Coactivation Analyses
*Session Chair †Invited, not yet responded.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
|
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
